The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 17%
- Matching filter
- 6
F·Filter
Reset allT1·Peer-primary literature
Randomized trials, peer-reviewed primary studies, and meta-analyses — the load-bearing layer of the corpus.
1 source
- 2025Reviewstrong
Retraction notice: 'The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System' and related Wright/Harding lab Dihexa publications
Journal of Pharmacology and Experimental Therapeutics (editorial) · Journal of Pharmacology and Experimental Therapeutics
April 2025 retraction notices removed two of the key Wright/Harding lab mechanism papers for Dihexa — Benoist 2014 on HGF/c-Met dependence and Kawas 2012 on AngIV analog development — following research-integrity investigations. The McCoy 2013 foundational paper has been under an expression of concern since 2021. The mechanism case for Dihexa is now substantially weaker than the public peptide-vendor literature acknowledges.
T2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
5 sources
- 2023Reviewstrong
Long COVID: major findings, mechanisms and recommendations
Davis HE, McCorkell L, Vogel JM, +1 · Nature Reviews Microbiology
At least 10% of SARS-CoV-2 infections produce a long-COVID syndrome, with more than 200 catalogued symptoms across multiple organ systems and an estimated 65 million affected globally — the cornerstone synthesis that consolidated the post-acute pathophysiology literature into a single mechanism framework.
- 2019Reviewstrong
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Davis SR, Baber R, Panay N, +13 · Climacteric
The ten-society global consensus narrows the testosterone-for-women indication to a single use case — postmenopausal HSDD — and explicitly recommends against compounded testosterone products at supraphysiologic dosing, the framework that anchors contemporary off-label prescribing under specialist supervision.
- 2019Reviewstrong
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft AJ, Bahat G, Bauer J, +15 · Age and Ageing
EWGSOP2 demoted muscle mass from primary diagnostic criterion to confirmatory finding and put strength first — the conceptual reframing that explains why so many peptide trials report lean-mass gains that do not move the clinical endpoint.
- 2018Reviewstrong
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Bhasin S, Brito JP, Cunningham GR, +7 · Journal of Clinical Endocrinology and Metabolism
The 2018 Endocrine Society guideline anchors the modern diagnosis: hypogonadism requires both unequivocally and consistently low morning total testosterone and symptoms or signs consistent with deficiency — biochemistry alone or symptoms alone do not qualify.
- 2015Reviewstrong
Ghrelin
Müller TD, Nogueiras R, Andermann ML, +9 · Molecular Metabolism
The 2015 multi-author Molecular Metabolism review that consolidated the ghrelin field — fifty co-authors spanning the major laboratories that built ghrelin pharmacology across two decades, covering the receptor, signaling, gastrointestinal and central effects, sleep-wake regulation, reward-seeking, and the pharmacological landscape of the secretagogue class.